ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves. DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics Further analyse

Vascepa gains event-reduction nod; diabetes ups ischemic risks.

Dec 20th, 2019 8m 16s

Vascepa approved for cardiovascular risk reduction The FDA’s decision on cutting events in high-risk patients was based primarily on the REDUCE-IT trial. ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding Novel oral

Post-STEMI events less likely in women; bariatric surgery may lower stroke risk

Dec 13th, 2019 7m 27s

Women have fewer cardiovascular events after non–ST-segment elevation ACS But they also remain undertreated with guideline-directed therapies. * * * Help us make this podcast better! Please take our short listener survey: https://www.surve

New trick for old drug; Vascepa cost effective for CV reduction

Dec 6th, 2019 7m 12s

Icosapent ethyl cost effective in REDUCE-IT analysis Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo. * * * Help us make this podcast better! Please take our short listener

Card Talk: TAVR and glass ceilings

Nov 29th, 2019 43m 4s

This week’s Cardiocast is devoted entirely to Card Talk with cardiologist brothers Jim and Jerry Dwyer. They welcome two structural interventionalists at the Structural Heart and Valve Center at Emory Healthcare, Kendra J. Grubb, MD, and Isid

ISCHEMIA trial, DAPA-HF, and valsartan recall: AHA Special

Nov 26th, 2019 32m 6s

In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner. The MDedge cardiology team reviews three big stories from the

Long-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF

Nov 22nd, 2019 8m 42s

ISCHEMIA trial hailed as practice changing The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves. * * * Help us make this podcast better! Please take our short listener survey

Pot heightens stroke, arrhythmia risks; keeping low LDL and BP slashes lifetime heart risk

Nov 15th, 2019 8m 2s

Getting high heightens stroke, arrhythmia risks Cannabis use or abuse among the young was associated with adverse cardiovascular consequences in two studies. * * * Help us make this podcast better! Please take our short listener survey: htt

How risk factors in childhood translate to CV outcomes in adulthood

Nov 8th, 2019 8m 33s

Closing the missing link between childhood risk factors and adult cardiovascular outcomes Prescient childhood cohort studies launched in the 1970s are paying off. * * * Help us make this podcast better! Please take our short listener survey:

Driving while defibrillating; hypertension holds greater risk in black patients

Nov 1st, 2019 7m 51s

Patients frequently drive too soon after ICD implantation Many patients didn’t recall ever receiving instruction about when to drive again. * * * Help us make this podcast better! Please take our short listener survey: https://www.surveymonkey

AFib hits Native Americans hard; TAVR shown durable, safe after 5 years

Oct 25th, 2019 7m 38s

Strong showing for TAVR after 5 years in PARTNER 2ATranscatheter and surgical aortic valve replacement had similar rates of death or disabling stroke. * * * Help us make this podcast better! Please take our short listener survey: https://w

Practice changing data from ESC 2019 Part II

Oct 22nd, 2019 42m 6s

MDedge reporters discuss the latest in practice-changing data from the 2019 annual congress of the European Society of Cardiology in Paris. Join Mitchel L. Zoler, Bruce Jancin, Kari Oakes, and MDedge Cardiology editor Catherine Hackett as they

Statins tied to skin, soft tissue infections; new Card Talk episode

Oct 18th, 2019 41m 38s

Statin use linked to risk of skin and soft tissue infections Use of statins was associated with increased risk of SSTIs at an average of 91, 182, and 365 days. Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS

Troponin protocol rapidly rules out MI; hidden risk of moderate aortic stenosis

Oct 11th, 2019 8m 51s

Novel cardiac troponin protocol rapidly rules out MI Three-quarters of patients who presented with suspected acute coronary syndrome were safely discharged from ED without hospital admission. Study questions preemptive TEVAR for extended type

Sun sets on longer DAPT after PCI; inactivity boosts post-MI risk

Oct 4th, 2019 8m 52s

Smoking and inactivity are the most powerful lifestyle risk factors after an MI Insufficient activity beats out obesity or above-target LDL cholesterol. Ticagrelor monotherapy tops DAPT for high-risk PCI patients TWILIGHT findings support mov

Cardiology dead last as women’s IM subspecialty choice

Sep 27th, 2019 7m 54s

Cardiology dead last as women’s IM subspecialty choice Women in internal medicine residencies were more likely than men to report that they had never considered cardiology as a career choice. Beta-blockers effective, safe for HFrEF with renal

An antiplatelet surprise; Europeans go low in cholesterol guidelines

Sep 20th, 2019 9m 15s

Prasugrel bests ticagrelor in ACS in surprise findings ISAR-REACT 5 was the first-ever direct head-to-head look at two potent P2Y12 inhibitors in this setting. European cholesterol guidelines push LDL targets below 55 mg/dL PCSK-9 inhibitors

SGLT-2 inhibitors and more practice changing data from ESC 2019

Sep 16th, 2019 22m 5s

Overweight BMI surpasses 'normal' and introducing the 'Card Talk' segment

Sep 13th, 2019 40m 36s

We introduce a brand new format with Jerome Dwyer, MD, brother of our host, Jim Dwyer, MD, for a new segment that we're calling 'Card Talk' where Dr. Jim and Dr. Jerry talk about the current clinical state of cardiology and take a peek into the

Dapgliflozin transomrs into heart failure drug

Sep 6th, 2019 9m 40s

DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug Proof that dapagliflozin significantly helped heart failure patients without diabetes recategorizes the drug as a major agent for treating heart failure. New

CV cost of smoking lasts a quarter century

Aug 30th, 2019 7m 35s

This week in cardiology: PCSK9 inhibition cuts events in very-high-risk groups ODYSSEY OUTCOMES analyses peg prior CABG and polyvascular disease as targets for alirocumab. Cardiovascular cost of smoking may last up to 25 years Past smokers f

Two FDA approvals, smoking impacts CV health for 25 years

Aug 23rd, 2019 8m 19s

TAVR valves now FDA approved for low-risk patients The FDA's decision will expand TAVR access to younger, healthier patients. FDA approves baroreflex activation for advanced HF A phase 4 trial will investigate impact on hospitalizations and

NSAIDS mediate CV risk and hypertension linked to dementia

Aug 16th, 2019 8m 6s

The top news in cardiology: Midlife hypertension linked to dementia risk Elevated blood pressure in midlife is associated with risk of subsequent dementia, but whether the risk is treatable is unclear. Ambulatory BP slightly better than

AI for AFib and acupuncture for angina

Aug 9th, 2019 9m 44s

The top stories in cardiology: Artificial intelligence technology meets AFib detection An AI-enabled ECG model suggests clinical implications for early identification of atrial fibrillation. Older patients who stop statins may be increasing

Seven simple rules of heart failure risk - you only need two

Aug 2nd, 2019 7m 51s

The top news in cardiology: Meeting just 2 of 7 ‘simple’ goals lowers HF risk American Heart Association recommendations seem to lower risk even if only a couple of the 'Simple 7' are mastered. Increased cardiovascular risk seen early on w